We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Neuronetics Inc | NASDAQ:STIM | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.31 | 8.86% | 3.81 | 3.60 | 5.02 | 3.86 | 3.50 | 3.59 | 41,783 | 05:00:00 |
The American Psychiatric Association is the leading professional psychiatric organization in the U.S. and is hosting virtual events this year May 1-3 in place of its traditional Annual Meeting, giving attendees a chance to experience sessions remotely. Neuronetics is a Gold sponsor of the event and will host two poster presentations on the company’s latest research with NeuroStar Advanced Therapy for Mental Health in patients with Major Depressive Disorder (MDD).
On Monday, May 3, Neuronetics will present real-world clinical data, addressing the following topics:
Neuronetics will also host a virtual exhibit booth at the event, offering attendees the opportunity to learn more about the NeuroStar Advanced Therapy for Mental Health treatment for MDD and its 5 STARS to Success Program for NeuroStar practices. Plan to visit and connect with someone from Neuronetics at the booth located within the “Virtual Exhibit Gallery” of the APA virtual meeting portal.
With 3.5 million treatments delivered across over 900 practice locations in the United States, Neuronetics continues to be a depression treatment industry leader. For more information, visit www.neurostar.com.
About NeuroneticsNeuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. Visit NeuroStar.com for safety information and indications for use. NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. Additional information can be found at www.neuronetics.com.
Media Contact:Chelsey MankoVault Communications610-455-2778cmanko@vaultcommunications.com
1 Year Neuronetics Chart |
1 Month Neuronetics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions